Some rare cases of recurrent Campylobacter bacteraemia (RCB) exist with relapses months to years after an effective treatment and a negativation of all bacterial samples. As of today, only around 20 cases have been described in the international literature for the last 30 years. The cases are likely highly underreported. No study describes those recurrent Campylobacter bacteraemias at the scale of a country. The aim of this multicentre, nationwide, retrospective study is to describe their precise epidemiology in France for the last 25 years, the immune profile of the patients, the specificities of the bacteria involved, the treatments received and the evolution of these infections. The perspective is to propose a standardization of the medical care of those patients mainly by describing the effective treatments and the explorations of the immune system which should be considered.
Study Type
OBSERVATIONAL
Enrollment
30
Variables: characteristics of the patients (demographic characteristics; characteristics of immunodeficiency: diagnosis, immunoglobulin dosage, white cells count etc.; chronic inflammatory bowel disease \[IBD\]), the bacteria (species, antimicrobial susceptibility) and the infection (clinical presentation, evolution, treatment received)
Infectious diseases department, Hospital de la Croix Rousse,
Lyon, France
Description of the characteristics of the patients presenting with recurrent Campylobacter bacteraemia
-demographic characteristics
Time frame: Baseline
Description of the characteristics of the patients presenting with recurrent Campylobacter bacteraemia
-characteristics of immunodeficiency: diagnosis, immunoglobulin dosage, white cells count, polyvalent Ig replacement therapy
Time frame: Baseline
Description of the characteristics of the patients presenting with recurrent Campylobacter bacteraemia
-chronic inflammatory bowel disease \[IBD\]
Time frame: Baseline
Description of the characteristics of the patients presenting with recurrent Campylobacter bacteraemia
-characteristics of bacteraemia: clinical presentation, bacteria (species, antimicrobial susceptibility), secondary localizations, evolution, treatment modalities (antibiotics and immunother
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.